Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Pulmonary Medicine
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1443749

The neutrophil-lymphocyte ratio predicts all-cause and cardiovascular mortality among U.S. adults with COPD: results from NHANES 1999-2018

Provisionally accepted
Zhao Chen Zhao Chen 1Wenqiang Li Wenqiang Li 2Yuanchun Tang Yuanchun Tang 3*Peng Zhou Peng Zhou 4*Qian He Qian He 5*Zhiping Deng Zhiping Deng 2*
  • 1 North Sichuan Medical College, Nanchong, China
  • 2 Zigong First People's Hospital, Zigong, Sichuan Province, China
  • 3 Zhengzhou University, Zhengzhou, Henan Province, China
  • 4 Changsha Medical University, Changsha, Hunan Province, China
  • 5 West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Background: Neutrophil-to-lymphocyte ratio (NLR) is considered a biomarker of systemic inflammation and immune activation. However, its relationship with the risk of mortality in patients with chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to investigate the association between NLR and the risk of all-cause and cardiovascular mortality in patients with COPD.Methods: Data were collected from the National Health and Nutrition Examination Survey (NHANES) from January 1999 to December 2018. The calculation method of NLR involves dividing the neutrophil count by the lymphocyte count in the total blood cell count. The optimal NLR threshold associated with survival outcomes was determined using the maximally selected rank statistics method (MSRSM). The relationship between NLR and the risk of all-cause mortality and cardiovascular mortality in COPD was investigated using a weighted multivariable Cox regression model. Additionally, restricted cubic spline (RCS) was employed to discuss the potential relationship between NLR patients in different groups and the risk of mortality.Results: In this study, 716 adults with COPD were included using the maximally selected rank statistics method, among whom 208 had higher NLR ( ≥ 2.56) and 508 had lower NLR (<2.56).During a median follow-up of 111.5 months, 162 COPD patients died from all causes, and 49 patients died from cardiovascular diseases. After adjusting for demographic, socioeconomic status, and lifestyle factors, the risk of all-cause mortality (HR=2.07, 95%CI: 1.46-2.94) and cardiovascular mortality (HR=3.03, 95%CI: 1.63-5.65) in patients with higher NLR was increased by 2-3 times compared to those with lower NLR. Kaplan-Meier analysis revealed significantly lower survival rates in patients with higher NLR for all-cause mortality and cardiovascular mortality (P<0.05). Restricted cubic spline analysis showed a linear correlation between NLR and the risk of all-cause mortality and cardiovascular mortality.NLR has a high value in independently predicting long-term all-cause and cardiovascular mortality risks in community-dwelling COPD patients. Therefore, NLR can serve as a cost-effective and widely available indicator for assessing the prognosis of COPD patients.

    Keywords: chronic obstructive pulmonary disease1, lymphocytes2, Neutrophils3, Mortality risk4, NHANES5

    Received: 04 Jun 2024; Accepted: 05 Sep 2024.

    Copyright: © 2024 Chen, Li, Tang, Zhou, He and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yuanchun Tang, Zhengzhou University, Zhengzhou, 450001, Henan Province, China
    Peng Zhou, Changsha Medical University, Changsha, 410219, Hunan Province, China
    Qian He, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China
    Zhiping Deng, Zigong First People's Hospital, Zigong, Sichuan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.